1661854-97-2 (TAS6417,Zipalertinib)

TAS6417;(S)-N-(4-amino-6-methyl-5-(quinolin-3-yl)-8,9-dihydropyrimido[5,4-b]indolizin-8-yl)acrylamide;NSC812926;s8814;Zipalertinib;BDBM50611355;GTPL11889;T4YMU8TW9H;TAS-6417;HY-112299;NSC-812926;TAS 6417;Zipalertinib [WHO-DD];Pan-mutation-selective EGFR Inhibitor CLN-081;EGFR Mutant-specific Inhibitor CLN-081;AKOS040742682;AS-79368;CLN-081;TPC-064;TPC064;AC-36462;SCHEMBL16525948;Zipalertinib [INN];N-[(8S)-4-amino-6-methyl-5-(quinolin-3-yl)-8H,9H-pyrimido[5,4-b]indolizin-8-yl]prop-2-enamide;Pan-mutation-selective EGFR Tyrosine Kinase Inhibitor CLN-081;N-[(8S)-4-Amino-6-methyl-5-quinolin-3-yl-8,9-dihydropyrimido[5,4-b]indolizin-8-yl]prop-2-enamide;EX-A3391;Cln 081;Pan-EGFR Inhibitor CLN-081;UNII-T4YMU8TW9H;CLN081;DA-78205;2-Propenamide, N-((8S)-4-amino-8,9-dihydro-6-methyl-5-(3-quinolinyl)pyrimido(5,4-b)indolizin-8-yl)-;CS-0044757;D93895;Mutation-specific EGFR TKI TAS6417;1661854-97-2;MKCYPWYURWOKST-INIZCTEOSA-N;CHEMBL4650281;

MFCD31715430

MKCYPWYURWOKST-INIZCTEOSA-N

1S/C23H20N6O/c1-3-18(30)28-16-8-13(2)21-19(15-9-14-6-4-5-7-17(14)25-10-15)20-22(24)26-12-27-23(20)29(21)11-16/h3-10,12,16H,1,11H2,2H3,(H,28,30)(H2,24,26,27)/t16-/m0/s1

O=C(C=C)N[C@H]1C=C(C)C2=C(C3C=NC4=CC=CC=C4C=3)C3=C(N)N=CN=C3N2C1